Healthcare Industry News: GenVec
News Release - September 19, 2006
GenVec Names Douglas J. Swirsky as Chief Financial Officer
GAITHERSBURG, Md.--(HSMN NewsFeed)--Sept. 19, 2006--GenVec, Inc. (Nasdaq:GNVC ), a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines, announced today the appointment of Douglas J. Swirsky as the Company's Chief Financial Officer, Treasurer and Corporate Secretary effective September 18, 2006. Mr. Swirsky was most recently a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus and held the same position at Legg Mason prior to Stifel Financial's acquisition of the Legg Mason Capital Markets Business in 2005.Mr. Swirsky, a Certified Public Accountant and a CFA charterholder, has also previously held investment banking positions at UBS, PaineWebber and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his B.S. in Business in Administration from Boston University and His Masters in Business Administration from the Kellogg School of Management at Northwestern University.
"The opportunity to work with Doug to build value for shareholders is a very exciting prospect," said GenVec's President and Chief Executive Officer Paul Fischer. "Doug's experience advising biotechnology companies and his ties with the investment community will provide a valuable new dimension to our management team."
About GenVec, Inc.
GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Additional information on GenVec and its portfolio of product candidates is available at www.GenVec.com and in the company's various filings with the Securities and Exchange Commission.
Source: GenVec
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!